The House Dust Mite Allergy Market, estimated to be valued at USD 2.96 Billion in 2025, is projected to witness a strong CAGR of 13.8%, reaching USD 7.32 Billion by 2032.

Growth is fueled by the rising prevalence of allergic rhinitis, asthma, and other dust mite–related conditions, alongside the increasing awareness of allergy diagnostics and immunotherapy solutions. Advancements in sublingual and subcutaneous immunotherapy, coupled with the improved availability of over-the-counter antihistamines and corticosteroids, are boosting treatment adoption.

Moreover, expanding healthcare access, regulatory approvals for innovative therapies, and growing investment in R&D for precision medicine approaches are expected to further drive the market expansion globally over the forecast period.

Market Takeaways

• By Treatment, the Pharmacotherapy segment is expected to dominate the house dust mite allergy market with a 61.7% share in 2025, driven by the widespread use of antihistamines, decongestants, nasal corticosteroids, and leukotriene receptor antagonists for rapid symptom relief and broad accessibility through prescription and OTC channels.
• By Diagnosis, Skin Prick Tests are anticipated to lead with a 50.8% market share in 2025, owing to their high diagnostic accuracy, low cost, and widespread availability in allergy clinics and primary care settings.
• By Allergy Type, Respiratory Allergies will account for the majority of the market share in 2025, supported by the rising prevalence of allergic rhinitis and asthma triggered by dust mite exposure, particularly in urban environments with poor indoor air quality.
• By Region, North America is expected to capture the largest market share in 2025, driven by the high awareness of allergy management, advanced diagnostic infrastructure, strong adoption of immunotherapy, and favorable reimbursement for allergy treatments.

House Dust Mite Allergy Market Report Coverage

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/house-dust-mite-allergy-market

Market Dynamics

The house dust mite allergy market is experiencing significant growth, driven by the rising global prevalence of allergic rhinitis, asthma, and other respiratory conditions triggered by dust mite exposure. Increasing urbanization, climate change impacts, and poor indoor air quality are amplifying allergen concentrations, leading to higher diagnosis rates. Greater awareness of allergy management, combined with advancements in pharmacotherapy—such as improved antihistamines, nasal corticosteroids, and leukotriene receptor antagonists—is enhancing symptom control and expanding treatment adoption.

A major growth catalyst is the increasing acceptance of allergen-specific immunotherapy, particularly sublingual immunotherapy (SLIT), which offers a convenient, non-invasive alternative to subcutaneous injections. Regulatory approvals of new SLIT tablets in the U.S., Europe, and Asia Pacific, alongside ongoing research into oral immunotherapy and biologics targeting IgE-mediated pathways, are broadening therapeutic options. The integration of advanced diagnostics, such as high-sensitivity skin prick tests and specific IgE blood assays, is facilitating early and accurate detection, enabling timely intervention.

The market is also benefiting from expanding healthcare infrastructure in emerging economies, supportive reimbursement policies in developed countries, and heightened investment in clinical trials for novel allergy therapeutics. However, challenges such as high treatment costs, limited patient adherence to long-term immunotherapy, and regional disparities in access to advanced allergy care may hinder market penetration.

In June 2024, at the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) held in Valencia, Spain (May 31–June 3, 2024), ALK-Abelló A/S unveiled results from two pivotal paediatric Phase 3 clinical trials. The MT-12 trial evaluated the efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet in children aged 5–11 years with HDM allergic rhinitis/rhinoconjunctivitis, with or without asthma. The TT-06 trial evaluated the SQ tree SLIT-tablet in children and adolescents aged 5–17 years with moderate to severe allergic rhinitis and/or conjunctivitis caused by birch and related tree pollens. ALK contributed 18 scientific abstracts in total, highlighting its leadership in advancing paediatric allergy immunotherapy research.

Market Trends

• Shift Toward Allergen-Specific Immunotherapy (AIT)

There is a growing preference for allergen-specific treatments such as sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT), driven by their disease-modifying potential compared to symptomatic pharmacotherapy. Recent regulatory approvals, including pediatric indications for SLIT tablets, are expanding patient eligibility.

In February 2025, the FDA approved an expanded indication for ALK's House Dust Mite Allergen Tablet (Odactra) to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, to include children aged 5 to 11 years, according to an announcement from ALK.

• Integration of Advanced Diagnostics

The adoption of precise diagnostic tools, such as component-resolved diagnostics (CRD) and high-sensitivity specific IgE assays, is enabling the accurate identification of allergens and the development of personalized treatment plans. This trend is supported by the wider availability of rapid point-of-care allergy testing.

In May 2023, Metropolis Healthcare, a leading diagnostic service provider in India, launched an AI-powered Component-Resolved Diagnostics platform capable of testing 127 respiratory, 10 contact, and 158 food allergens. This platform empowers clinicians to make informed treatment decisions through highly precise allergen identification.

Market Opportunities

• Integration of AI-Driven Allergy Diagnostics

The rise of AI-powered component-resolved diagnostics (CRD) and multiplex IgE assays creates opportunities for providers to offer precision diagnosis packages linked directly to tailored treatment plans. Partnerships between pharma and diagnostic firms could streamline the “test-to-treat” pathway, improving treatment uptake rates.

In June 2025, innovation introduced the Skin Prick Automated Test (SPAT) device that uses AI and image segmentation for precise wheal detection. The system captures multiple images under varied lighting conditions and applies neural network–based segmentation to increase diagnostic accuracy over conventional single-image methods.

• Combination Therapies with Biologics

Emerging clinical research and real-world evidence are increasingly supporting the synergistic potential of combining allergen immunotherapy (AIT) with biologics such as anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab), and anti-IL-4R (dupilumab) agents. This dual approach can accelerate symptom relief, improve asthma control, and enhance long-term disease modification in patients with severe house dust mite (HDM) allergy—particularly those with comorbid allergic asthma or multiple atopic conditions. Biologics can help reduce the initial adverse reactions sometimes associated with AIT initiation, thereby improving patient adherence and enabling higher maintenance doses earlier in therapy.

In high-income markets with favorable reimbursement environments, this strategy represents a premium treatment segment with strong commercial potential. The approach is particularly relevant for difficult-to-treat populations, such as patients with high baseline IgE levels or poor control on standard therapy. Ongoing Phase II and III trials are exploring these combinations, with early findings suggesting improved lung function, reduced exacerbations, and enhanced quality-of-life scores compared to monotherapy. This creates opportunities for pharma–biotech partnerships to develop integrated therapeutic packages, co-marketing strategies, and bundled reimbursement models that could accelerate market adoption once more robust clinical evidence emerges.

Analyst View

• The house dust mite allergy market is set for robust expansion through 2032, propelled by the rising global prevalence of allergic rhinitis, asthma, and other HDM-triggered respiratory disorders. Growth momentum is being fueled by advancements in allergen-specific immunotherapy (AIT), broader adoption of precision diagnostics, and a shift toward combination treatment strategies incorporating biologics. The expanding patient pool and improving treatment accessibility in key regions are reinforcing this upward trajectory.
• On the diagnostic front, the integration of high-sensitivity skin prick tests, AI-powered component-resolved diagnostics (CRD), and multiplex IgE assays is reshaping early detection and patient stratification. These technologies enable allergists to pinpoint allergen sensitivities with greater accuracy, supporting personalized immunotherapy regimens. Innovations such as AI-driven wheel measurement systems and rapid point-of-care testing are streamlining the test-to-treat pathway, particularly in urban primary care and specialty clinic settings. Supportive regulatory and reimbursement environments in North America and Europe are accelerating adoption, while expanding healthcare infrastructure in the Asia Pacific is opening new high-growth opportunities.
• Therapeutically, the market is shifting toward disease-modifying approaches. Sublingual immunotherapy (SLIT) continues to gain traction due to its non-invasive delivery and patient convenience, with recent pediatric label expansions (e.g., ALK’s Odactra) widening the eligible population. Emerging evidence supporting the combination of AIT with biologics—such as omalizumab (anti-IgE), mepolizumab (anti-IL-5), and dupilumab (anti-IL-4R)—is particularly promising for severe or multi-sensitized patients. These regimens can accelerate symptom relief, improve asthma control, and reduce AIT-related adverse events, creating a premium therapeutic niche in high-income markets with favorable reimbursement frameworks.
• Regionally, North America is expected to maintain its leadership, supported by advanced diagnostic capabilities, strong immunotherapy uptake, and comprehensive insurance coverage. Europe remains a key growth hub, with regulatory alignment across major markets facilitating faster adoption of newly approved SLIT formulations. Asia Pacific is projected to experience the most rapid growth, driven by rising urbanization, environmental changes, and increased middle-class healthcare spending that boosts both diagnosis rates and therapy adoption.
• From an investment perspective, the HDM allergy space offers substantial opportunities across diagnostics, immunotherapy innovation, and biologic-AIT combinations. Strategic collaborations between diagnostic providers and biopharma companies could unlock integrated care models, while bundled reimbursement strategies may enhance the adoption of premium therapies. Nonetheless, high treatment costs, long-term adherence challenges for AIT, and disparities in access to advanced allergy care across regions remain significant hurdles.

Recent Key Developments

In December 2024, Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had provided a positive opinion for the extension of the existing indication for Palforzia (defatted powder of Arachis hypogaea L., semen (peanuts)) to the treatment of toddlers (ages 1 to 3) with a confirmed diagnosis of peanut allergy. If the extension indication is granted by the European Commission, Palforzia will become the first EMA-approved oral immunotherapy (OIT) treatment for toddlers living with confirmed peanut allergy.

Competitive Landscape

• ALK-Abelló A/S
• Stallergenes Greer
• HAL Allergy Group
• Allergy Therapeutics
• Anergis SA
• T-Balance Therapeutics
• Worg Pharmaceuticals
• Advagene Biopharma Co., Ltd.
• Immunotek SL
• Tolerogenics S.à.r.l.
• Foresee Pharmaceuticals

House Dust Mite Allergy Market Segmentation

• By Treatment
• Pharmacotherapy
• Antihistamines
• Decongestants
• Nasal Corticosteroids
• Leukotriene Receptor Antagonists
• Immunotherapy
• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
• Oral Immunotherapy
• By Diagnosis
• Skin Prick Tests
• Specific IgE Blood Tests
• Patch Tests
• By Allergy Type
• Respiratory Allergies
• Allergic Rhinitis
• Allergic Asthma
• Dermatological Allergies
• Atopic Dermatitis
• Eczema

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • France
  • Russia
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • Japan
  • China
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of the Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa